Strategies for antiviral therapy in AIDS
|
journal
|
February 1987 |
Active human immunodeficiency virus protease is required for viral infectivity.
|
journal
|
July 1988 |
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
|
journal
|
August 2010 |
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
|
journal
|
March 2006 |
Current status and challenges of antiretroviral research and therapy
|
journal
|
January 2010 |
Why do patients fail HIV therapy?: Why do patients fail HIV therapy?
|
journal
|
May 2007 |
Principles and practice of HIV-protease inhibitor pharmacoenhancement: HIV-protease inhibitor pharmacoenhancement
|
journal
|
April 2001 |
Mortality and progression to AIDS after starting highly active antiretroviral therapy
|
journal
|
January 2003 |
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
|
journal
|
December 1999 |
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
|
journal
|
January 2010 |
Bis-Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance
|
journal
|
September 2006 |
Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance
|
journal
|
August 2006 |
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
|
journal
|
December 2007 |
Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro
|
journal
|
September 2003 |
TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates
|
journal
|
May 2005 |
High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-peptide Inhibitor (UIC-94017) Active Against Multi-drug-resistant Clinical Strains
|
journal
|
April 2004 |
Enhancing Protein Backbone Binding-A Fruitful Concept for Combating Drug-Resistant HIV
|
journal
|
January 2012 |
Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance
|
journal
|
January 2008 |
Design, Synthesis, and X-ray Structure of Substituted Bis-tetrahydrofuran (Bis-THF)-Derived Potent HIV-1 Protease Inhibitors
|
journal
|
January 2011 |
Design of gem -Difluoro- bis -Tetrahydrofuran as P2 Ligand for HIV-1 Protease Inhibitors to Improve Brain Penetration: Synthesis, X-ray Studies, and Biological Evaluation
|
journal
|
October 2014 |
GRL-04810 and GRL-05010, Difluoride-Containing Nonpeptidic HIV-1 Protease Inhibitors (PIs) That Inhibit the Replication of Multi-PI-Resistant HIV-1 In Vitro and Possess Favorable Lipophilicity That May Allow Blood-Brain Barrier Penetration
|
journal
|
September 2013 |
Synthesis of 1,2- O -Isopropylidene-L-threitol and its Conversion to ( R )-1,2- O -Isopropylideneglycerol
|
journal
|
January 1985 |
Cesium promoted O-alkylation of alcohols for the efficient ether synthesis
|
journal
|
March 1999 |
Asymmetric Induction in the [2,3] Wittig Rearrangement by Chiral Substituents in the Allyl Moiety
|
journal
|
February 1988 |
Asymmetric Induction and Simple Diastereoselectivity in the [2,3] Wittig Rearrangement of Ester Enolates
|
journal
|
April 1989 |
Mitsunobu and Related Reactions: Advances and Applications
|
journal
|
June 2009 |
A Convergent Synthesis of (+)-Cryptophycin B, a Potent Antitumor Macrolide from Nostoc sp. Cyanobacteria
|
journal
|
June 2000 |
A simple, continuous fluorometric assay for HIV protease
|
journal
|
December 1990 |
The role of dolutegravir in the management of HIV infections
|
journal
|
February 2015 |
Prevalence of Darunavir Resistance–Associated Mutations: Patterns of Occurrence and Association with Past Treatment
|
journal
|
October 2007 |
In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors
|
journal
|
September 2010 |
Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease Inhibitors
|
journal
|
February 2002 |
Loss of Protease Dimerization Inhibition Activity of Darunavir Is Associated with the Acquisition of Resistance to Darunavir by HIV-1
|
journal
|
August 2011 |
Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir
|
journal
|
August 2014 |
Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes
|
journal
|
January 2001 |
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters: HIV protease mutants altering hydrophobic clusters
|
journal
|
August 2010 |
Phaser crystallographic software
|
journal
|
July 2007 |
Overview of the CCP 4 suite and current developments
|
journal
|
March 2011 |
A graphical user interface to the CCP 4 program suite
|
journal
|
June 2003 |
Features and development of Coot
|
journal
|
March 2010 |
PRODRG : a tool for high-throughput crystallography of protein–ligand complexes
|
journal
|
July 2004 |